Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2019 Feb 14;25(7):e226–e246. doi: 10.1016/j.bbmt.2019.02.012

Table 7.

MPS VII with HSCT

Author Details Results
Yamada et al 1998 [20]
  • 12-year old female

  • Donor source: HLA-identical unrelated female

  • Multiple disease symptoms at transplantation

  • Wheelchair-bound

  • Rectal mucosa swollen with lysosomal storage material

  • No GVHD

  • Congestive heart failure at day 6, resolved at day 55 post-transplantation

  • Interstitial pneumonia from cytomegalovirus 37 days after transplantation

  • Uronic acid decreased from 44 mg/g to 14 mg/g

  • Swollen lysosomal storage material in the patient’s rectal mucosa discontinued

  • Recurrent infections ceased

  • Improved motor function, shortness of breath, recurrent infections and snoring

  • IQ was not significantly altered (IQ of 47 reported after BMT)

  • Brain atrophy and ventricular enlargement did not change significantly

  • Moderate aortic valve and mitral valve regurgitation did not change but was stabilized

  • No changes in vertebrae or hip joints

  • Quality of life improved

Montano et al. 2016 [180]
  • 5 Patients

  • Patient 1:

  • BMT at age 2 - failed

  • Second BMT at age 4 - successful

  • Patient 2:

  • Seven years old, severe manifestations

  • Patient 3:

  • Diagonosed at 4 months of age

  • Patient 4:

  • BMT at 3 years of age

  • Patient 5:

  • BMT at 7 months

  • Patient 1: moderate clinical and skeletal manifestations, normal intelligence

  • Overall slow progression of disease

  • Patient 2: Died from complication of BMT

  • Patient 3: Died few years after BMT

  • Patient 4: Moderate phenotype at age of 15

  • Displays clinical and skeletal manifestations

  • Hydrocephalic with language impairment

  • Patient 5: No clinical manifestations at 15 months of age

  • Hepatomegaly disappeared, normal intelligence, and walking

  • Cardiomyopathy with mild atrial enlarement

Sisinni et al. 2018 [182]
  • 2-year old female

  • 1st transplantation: Matched unrelated donor

  • Reduced intensity fludarabine, melphalan, and alemtuzumab

  • 2nd transplantation: matched unrelated cord blood

  • Myeloabalative busulfan, cyclophosphamide, and ATG

  • Developed aGvHD

  • 1st transplantation: Graft rejected 1-year after transplantation

  • Second HSCT performed:

  • Full chimerism +6 years after transplant

  • Normal motor function, stabalized skeletal dysplasia

  • No neurological symptoms present